Three-dimensional Structure of a Mutant HIV-1 Protease Displaying Cross-resistance to All Protease Inhibitors in Clinical Trials (*)

Analysis of mutational effects in the human immunodeficiency virus type-1 (HIV-1) provirus has revealed that as few as four amino acid side-chain substitutions in the HIV-1 protease (M46I/L63P/V82T/I84V) suffice to yield viral variants cross-resistant to a panel of protease inhibitors either in or being considered for clinical trials (Condra, J. H., Schleif, W. A., Blahy, O. M., Gadryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. A. (1995) Nature 374, 569-571). As an initial effort toward elucidation of the molecular mechanism of drug resistance in AIDS therapies, the three-dimensional structure of the HIV-1 protease mutant containing the four substitutions has been determined to 2.4-Å resolution with an R factor of 17.1%. The structure of its complex with MK639, a protease inhibitor of the hydroxyaminopentane amide class of peptidomimetics currently in Phase III clinical trials, has been resolved at 2.0 Å with an R factor of 17.0%. These structures are compared with those of the wild-type enzyme and its complex with MK639 (Chen, Z., Li, Y., Chen, E., Hall, D. L., Darke, P. L., Culberson, C., Shafer, J., and Kuo, L. C.(1994) J. Biol. Chem. 269, 26344-26348). There is no gross structural alteration of the protease due to the site-specific mutations. The C tracings of the two native structures are identical with a root-mean-square deviation of 0.5 Å, and the four substituted side chains are clearly revealed in the electron density map. In the MK639-bound form, the V82T substitution introduces an unfavorable hydrophilic moiety for binding in the active site and the I84V substitution creates a cavity (unoccupied by water) that should lead to a decrease in van der Waals contacts with the inhibitor. These changes are consistent with the observed 70-fold increase in the K value (2.5 kcal/mol) for MK639 as a result of the mutations in the HIV-1 protease. The role of the M46I and L63P substitutions in drug resistance is not obvious from the crystallographic data, but they induce conformational perturbations (0.9-1.1 Å) in the flap domain of the native enzyme and may affect the stability and/or activity of the enzyme unrelated directly to binding.

[1]  L. Kuo,et al.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.

[2]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[3]  Richman Dd Human immunodeficiency virus. Protease uninhibited. , 1995 .

[4]  John W. Erickson,et al.  Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase , 1995, Nature Structural Biology.

[5]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Kuo,et al.  Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates. , 1994, Biochemistry.

[7]  H. Mitsuya,et al.  High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. , 1993, The Journal of pediatrics.

[8]  J. Tang,et al.  Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. , 1991, The Journal of biological chemistry.

[9]  R. Poljak,et al.  The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. , 1991, Biochimie.

[10]  Corwin Hansch,et al.  α-Chymotrypsin: A Case Study of Substituent Constants and Regression Analysis in Enzymic Structure—Activity Relationships , 1970 .

[11]  E. Chen Host strain selection for bacterial expression of toxic proteins. , 1994, Methods in enzymology.

[12]  T. Merigan,et al.  Textbook of AIDS Medicine , 1994 .

[13]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[14]  P. Andrews,et al.  Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.